TAKEDA PHARMACEUTICAL CO LTD
TKPHFDrugs in Pipeline
92
Phase 3 Programs
68
Upcoming Catalysts
6
Next Catalyst
Oct 2026
Market Overview
Stock performance and key metrics
6 upcoming, 1 past
Epoetin Alfa
Myelodysplastic Syndrome
rVWF
Von Willebrand Disease (VWD)
TAK-928
IO-resistant sqNSCLC
TAK-875
Diabetes Mellitus
Alogliptin and pioglitazone
Type 2 Diabetes Mellitus
TVP-1012 1mg
Parkinson's Disease
Vedolizumab SC
Colitis, Ulcerative
Lapaquistat acetate
Hypercholesterolemia
TAK-788
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
TAP-144-SR(6M)
Premenopausal Breast Cancer
Teduglutide
Short Bowel Syndrome
Mezagitamab
Kidney Disease
Tetravalent Dengue Vaccine (TDV)
Dengue Fever
Pioglitazone and metformin
Diabetes Mellitus
TAK-881
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Allopurinol
Gout
omega-3-acid ethyl esters 90 (TAK-085)
Hypertriglyceridemia
TAK-625
Progressive Familial Intrahepatic Cholestasis (PFIC)
TAK-861
Narcolepsy Type 1
Lanadelumab
Hereditary Angioedema (HAE)
TAK-019
Coronavirus Disease (COVID-19)
Valsartan
Hypertension
Elritercept
Myelodysplastic Syndromes
Azilsartan medoxomil with or without add-on chlorthalidone
Hypertension
rozerem
Insomnia
Ponatinib
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Relugolix
Uterine Fibroids
Apremilast
Plaque Psoriasis
Bismuth-Containing Quadruple Therapy
Gastric Ulcer
Vedolizumab IV
Ulcerative Colitis
Vortioxetine
Depressive Disorder, Major
TAK-438
Duodenal Ulcer
Lansoprazole
Gastric Ulcers
Alogliptin
Type 2 Diabetes Mellitus
Vedolizumab
Ulcerative Colitis
Zasocitinib
Plaque Psoriasis
Febuxostat
Hyperuricosuria
Ramelteon
Chronic Insomnia
TDV
Healthy Volunteers
Lubiprostone
Chronic Idiopathic Constipation
Febuxostat IR
Gout
Lapaquistat acetate and atorvastatin
Dyslipidemia
TAK-360
Narcolepsy Type 2
Vonoprazan
Helicobacter Pylori
Alogliptin and insulin
Diabetes Mellitus
Alogliptin and metformin
Diabetes Mellitus
Trelagliptin 25 mg
Type 2 Diabetes Mellitus
ciclesonide (XRP1526)
Respiratory Tract Diseases
Alogliptin 25 mg
Diabetes Mellitus
IGI, 10%
Multiple Myeloma
Soticlestat
15q Duplication Syndrome
Alogliptin and voglibose
Type 2 Diabetes Mellitus
SYR-472
Type 2 Diabetes Mellitus
Dexlansoprazole MR
Esophagitis, Reflux
Dexlansoprazole
Gastroesophageal Reflux Disease (GERD)
TAK-771
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Fazirsiran Injection
Alpha1-Antitrypsin Deficiency
Ixazomib
Multiple Myeloma
Maribavir
Cytomegalovirus (CMV)
Azilsartan medoxomil
Hypertension
TAK-279
Ulcerative Colitis
Azilsartan medoxomil and chlorthalidone
Safety
Chlorthalidone
Hypertension
Actovegin
Post-Stroke Cognitive Impairment (PSCI)
Peginesatide
Anemia
Darvadstrocel
Complex Perianal Fistulas in Adult Participants With Crohn's Disease
Azilsartan
Pediatric Hypertension
HYQVIA
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
TAK-935
Epilepsy
Vedolizumab 300 MG Injection [Entyvio]
Immune Checkpoint Inhibitor-Related Colitis
TAK-850
Influenza
Idursulfase-IT
Hunter Syndrome
TAK-226
Myelodysplastic Syndromes
TAK-583
Diabetic Neuropathies
TAK-079
Myasthenia Gravis
TAK-385
Endometriosis
Immune Globulin Infusion (Human), 10% Solution
Hematologic Malignancies
Tak-228 & Tak-117
Triple Negative Breast Cancer
Adcetris-Levact
Clinical Efficacy
Brentuximab Vedotin
Hodgkin Disease
Ramelteon and gabapentin
Sleep Initiation and Maintenance Disorders
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
Colorectal Carcinoma
Rusfertide
Polycythemia Vera
Voglibose
Diabetes Mellitus, Type 2
Niraparib
Ovarian Cancer
Glimepiride
Diabetes Mellitus, Type 2
TAK-954
Diabetic Gastroparesis
Brigatinib
NSCLC
TAK-755
Thrombotic Thrombocytopenic Purpura (TTP)
Namilumab
Plaque Psoriasis
TAK-505
Malignant Solid Tumors
NoV GI.1/GII.4 Bivalent VLP Vaccine
Healthy Volunteers
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Epoetin Alfa | Phase 3 | Myelodysplastic Syndrome | - | - |
rVWF | Phase 3 | Von Willebrand Disease (VWD) | - | - |
TAK-928 | Phase 3 | IO-resistant sqNSCLC | - | - |
TAK-875 | Phase 3 | Diabetes Mellitus | - | - |
Alogliptin and pioglitazone | Phase 3 | Type 2 Diabetes Mellitus | - | - |
TVP-1012 1mg | Phase 3 | Parkinson's Disease | - | - |
Vedolizumab SC | Phase 3 | Colitis, Ulcerative | - | - |
Lapaquistat acetate | Phase 3 | Hypercholesterolemia | - | - |
TAK-788 | Phase 3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | - | - |
TAP-144-SR(6M) | Phase 3 | Premenopausal Breast Cancer | - | - |
Teduglutide | Phase 3 | Short Bowel Syndrome | - | - |
Mezagitamab | Phase 3 | Kidney Disease | - | - |
Tetravalent Dengue Vaccine (TDV) | Phase 3 | Dengue Fever | - | - |
Pioglitazone and metformin | Phase 3 | Diabetes Mellitus | - | - |
TAK-881 | Phase 3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | - | - |
Allopurinol | Phase 3 | Gout | - | - |
omega-3-acid ethyl esters 90 (TAK-085) | Phase 3 | Hypertriglyceridemia | - | - |
TAK-625 | Phase 3 | Progressive Familial Intrahepatic Cholestasis (PFIC) | - | - |
TAK-861 | Phase 3 | Narcolepsy Type 1 | - | - |
Lanadelumab | Phase 3 | Hereditary Angioedema (HAE) | - | - |
TAK-019 | Phase 3 | Coronavirus Disease (COVID-19) | - | - |
Valsartan | Phase 3 | Hypertension | - | - |
Elritercept | Phase 3 | Myelodysplastic Syndromes | - | - |
Azilsartan medoxomil with or without add-on chlorthalidone | Phase 3 | Hypertension | - | - |
rozerem | Phase 3 | Insomnia | - | - |
Ponatinib | Phase 3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | - | - |
Relugolix | Phase 3 | Uterine Fibroids | - | - |
Apremilast | Phase 3 | Plaque Psoriasis | - | - |
Bismuth-Containing Quadruple Therapy | Phase 3 | Gastric Ulcer | - | - |
Vedolizumab IV | Phase 3 | Ulcerative Colitis | - | - |
Vortioxetine | Phase 3 | Depressive Disorder, Major | - | - |
TAK-438 | Phase 3 | Duodenal Ulcer | - | - |
Lansoprazole | Phase 3 | Gastric Ulcers | - | - |
Alogliptin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Vedolizumab | Phase 3 | Ulcerative Colitis | - | - |
Zasocitinib | Phase 3 | Plaque Psoriasis | - | - |
Febuxostat | Phase 3 | Hyperuricosuria | - | - |
Ramelteon | Phase 3 | Chronic Insomnia | - | - |
TDV | Phase 3 | Healthy Volunteers | - | - |
Lubiprostone | Phase 3 | Chronic Idiopathic Constipation | - | - |
Febuxostat IR | Phase 3 | Gout | - | - |
Lapaquistat acetate and atorvastatin | Phase 3 | Dyslipidemia | - | - |
TAK-360 | Phase 3 | Narcolepsy Type 2 | - | - |
Vonoprazan | Phase 3 | Helicobacter Pylori | - | - |
Alogliptin and insulin | Phase 3 | Diabetes Mellitus | - | - |
Alogliptin and metformin | Phase 3 | Diabetes Mellitus | - | - |
Trelagliptin 25 mg | Phase 3 | Type 2 Diabetes Mellitus | - | - |
ciclesonide (XRP1526) | Phase 3 | Respiratory Tract Diseases | - | - |
Alogliptin 25 mg | Phase 3 | Diabetes Mellitus | - | - |
IGI, 10% | Phase 3 | Multiple Myeloma | - | - |
Soticlestat | Phase 3 | 15q Duplication Syndrome | - | - |
Alogliptin and voglibose | Phase 3 | Type 2 Diabetes Mellitus | - | - |
SYR-472 | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Dexlansoprazole MR | Phase 3 | Esophagitis, Reflux | - | - |
Dexlansoprazole | Phase 3 | Gastroesophageal Reflux Disease (GERD) | - | - |
TAK-771 | Phase 3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | - | - |
Fazirsiran Injection | Phase 3 | Alpha1-Antitrypsin Deficiency | - | - |
Ixazomib | Phase 3 | Multiple Myeloma | - | - |
Maribavir | Phase 3 | Cytomegalovirus (CMV) | - | - |
Azilsartan medoxomil | Phase 3 | Hypertension | - | - |
TAK-279 | Phase 3 | Ulcerative Colitis | - | - |
Azilsartan medoxomil and chlorthalidone | Phase 3 | Safety | - | - |
Chlorthalidone | Phase 3 | Hypertension | - | - |
Actovegin | Phase 3 | Post-Stroke Cognitive Impairment (PSCI) | - | - |
Peginesatide | Phase 3 | Anemia | - | - |
Darvadstrocel | Phase 3 | Complex Perianal Fistulas in Adult Participants With Crohn's Disease | - | - |
Azilsartan | Phase 3 | Pediatric Hypertension | - | - |
HYQVIA | Phase 3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | - | - |
TAK-935 | Phase 2 | Epilepsy | - | - |
Vedolizumab 300 MG Injection [Entyvio] | Phase 2 | Immune Checkpoint Inhibitor-Related Colitis | - | - |
TAK-850 | Phase 2 | Influenza | - | - |
Idursulfase-IT | Phase 2 | Hunter Syndrome | - | - |
TAK-226 | Phase 2 | Myelodysplastic Syndromes | - | - |
TAK-583 | Phase 2 | Diabetic Neuropathies | - | - |
TAK-079 | Phase 2 | Myasthenia Gravis | - | - |
TAK-385 | Phase 2 | Endometriosis | - | - |
Immune Globulin Infusion (Human), 10% Solution | Phase 2 | Hematologic Malignancies | - | - |
Tak-228 & Tak-117 | Phase 2 | Triple Negative Breast Cancer | - | - |
Adcetris-Levact | Phase 2 | Clinical Efficacy | - | - |
Brentuximab Vedotin | Phase 2 | Hodgkin Disease | - | - |
Ramelteon and gabapentin | Phase 2 | Sleep Initiation and Maintenance Disorders | - | - |
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab | Phase 2 | Colorectal Carcinoma | - | - |
Rusfertide | Phase 2 | Polycythemia Vera | - | - |
Voglibose | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Niraparib | Phase 2 | Ovarian Cancer | - | - |
Glimepiride | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
TAK-954 | Phase 2 | Diabetic Gastroparesis | - | - |
Brigatinib | Phase 2 | NSCLC | - | - |
TAK-755 | Phase 2 | Thrombotic Thrombocytopenic Purpura (TTP) | - | - |
Namilumab | Phase 2 | Plaque Psoriasis | - | - |
TAK-505 | Phase 2 | Malignant Solid Tumors | - | - |
NoV GI.1/GII.4 Bivalent VLP Vaccine | Phase 2 | Healthy Volunteers | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in TAKEDA PHARMACEUTICAL CO LTD's drug pipeline?→
CatalystAlert tracks 92 drug candidates in TAKEDA PHARMACEUTICAL CO LTD's (TKPHF) pipeline across Phase 3, Phase 2. Its lead program is Epoetin Alfa (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is TAKEDA PHARMACEUTICAL CO LTD's next FDA catalyst?→
TAKEDA PHARMACEUTICAL CO LTD's (TKPHF) next tracked catalyst is a Phase 3 expected October 2, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TKPHF biotech catalysts?→
Add TKPHF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TAKEDA PHARMACEUTICAL CO LTD's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.